NIKKEI 225
39,103.22 +486.12 (+1.26%) HANG SENG
18,868.71 -326.89 (-1.70%) CRUDE OIL
76.85 -0.72 (-0.93%) GOLD FUTURES
2,350.60 -42.30 (-1.77%) DOW
39,391.77 -279.27 (-0.70%) Bitcoin GBP
53,414.13 -2,115.07 (-3.81%)
Medincell SA (MEB.BE)
| Previous close | 14.24 |
| Open | 14.34 |
| Bid | 14.24 x N/A |
| Ask | 14.96 x N/A |
| Day's range | 14.30 - 14.60 |
| 52-week range | 5.42 - 16.78 |
| Volume | |
| Avg. volume | 16 |
| Market cap | N/A |
| Beta (5Y monthly) | N/A |
| PE ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- Business Wire
Medincell to Present at the 2024 Jefferies Global Healthcare Conference, June 4 to 6, 2024, New York
MONTPELLIER, France, May 21, 2024--Regulatory News: Medincell (Paris:MEDCL):
- Business Wire
Medincell Provides Update on Phase 3 mdc-CWM Clinical Trial
MONTPELLIER, France, May 14, 2024--Regulatory News: Medincell (Paris:MEDCL) today announced that the Phase 3 trial for F14 (mdc-CWM) being conducted by Arthritis Innovation Corporation (AIC) did not meet its primary endpoint of time-weighted AUC1 of pain intensity over 14 days when comparing treatment with multimodal analgesia (MMA) alone to MMA concurrent with a single dose of F14 administered in the knee at the time of Total Knee Replacement (TKR). The MMA control analgesia that every patient
- Business Wire
Medincell to Host Videoconference on May 15, 2024, at 10:30 AM CEST to Discuss Company's Latest News, Outlook, and R&D Activities
MONTPELLIER, France, May 13, 2024--Regulatory News: Medincell (Paris:MEDCL) is a clinical- and commercial-stage biopharmaceutical licensing company developing long-acting injectable drugs in many therapeutic areas. The first treatment based on BEPO® technology, aimed at treating schizophrenia, was approved by the FDA in April 2023, and has since been distributed in the United States by Teva under the name UZEDY® (BEPO® technology is licensed to Teva under the name SteadyTeq™).
